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Summary. The effects on the pituitary-adrenocortical 
functions of the prolonged (7-day) blockade of 
endogenous bradykinin (BK) synthesis, obtained by the 
administration of the kallikrein inhibitor (K-I)  
cyclohexylacetyl-Phe-Arg-Ser-Val-Gln amide, were 
investigated i n  the rat. K-I treatment did not cause 
significant changes in the (i) body and adrenal weights; 
(ii) basal plasma levels of ACTH, aldosterone and 
corticosterone; and (iii) average volume of adreno- 
cortical cells and their basal secretory capacity. 
Conversely, K-I administration induced a significant 
magnification of the in vivo mineralo- and glucocorticoid 
responses to the intraperitoneal (i.p.) bolus injection of 
ACTH. Moreover, K-I-treated rats, but not control ones, 
displayed a moderate and short-term adrenal secretory 
response to the mild stress evoked by the placebo i.p. 
injection. Collectively, these findings rule out the 
possibility that endogenous BK plays a relevant role in 
the control of adrenocortical function under basal 
conditions. However, they suggest that endogenous BK 
may be involved in quenching exceedingly high 
adrenocortical responses to ACTH and stresses. 
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Introduction 
Bradykinin (BK) is a vasodilatory peptide, which 
acts through two subtypes of receptors called RI  and B2. 
B1 receptor is mainly expressed in the aorta, whereas B2 
subtype is widely distributed in the body. BK synthesis 
from a2-globulins (kininogens) is catalyzed by 
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kallikreins, which are distinct in plasma and tissue 
kallikreins (for review, see Bathon and Proud, 1991; 
Margolius, 1996). 
Tissue-kallikrein protein and mRNA have been 
demonstrated in the rat adrenal gland, thereby indicating 
the local synthesis of BK (Scicli et al., 1991; Nolly et al., 
1993). The possibility that BK may be included in that 
group of peptides involved in the paracrinetautocrine 
regulation of adrenocortical secretion (for review, see 
Nussdorfer, 1996; Mazzocchi et al., 1998) is suggested 
by the following lines of evidence. BK, acting via B2 
receptors, was found to stimulate in vitro aldosterone 
production by bovine and rat zona glomerulosa (ZG) 
cells (Rosolowsky and Campbell, 1992; Malendowicz et 
al., 1995b) and corticosterone secretion by dispersed rat 
zona fasciculata-reticularis (ZFIR) cells (Malendowicz et 
al., 1995a). Moreover, BK has been reported to hamper 
the secretory responses of dispersed adrenocortical cells 
to ACTH (Malendowicz et al., 1995a,b). 
In vivo investigations, using acute or prolonged 
administration of BK and B2-receptor antagonists, gave 
conflicting and rather disappointing results, collectively 
suggesting that endogenous BK does not play a relevant 
role in the physiological control of the adrenocortical 
functions under basal conditions (Rudichenko et al., 
1993; Malendowicz et al., 1995c, 1996a). However, the 
selectivity of the BK-receptor antagonists employed, as 
well as their effectiveness in producing a long-term 
blockade of BK actions are questionable. Therefore, it 
seemed worthwhile to study whether the prolonged 
blockade of BK synthesis by a selective tissue-kallikrein 
inhibitor (K-I) is able to modify the secretion and growth 
of rat adrenal cortex. 
Materials and methods 
Reagents and animals 
The K-I cyclohexylacetyl-Phe-Arg-Ser-Val-Gln 



